GCN2 deficiency ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and myocardial oxidative stress

The clinical use of doxorubicin for cancer therapy is limited by its cardiotoxicity, which involves cardiomyocyte apoptosis and oxidative stress. Previously, we showed that general control nonderepressible 2 (GCN2), an eukaryotic initiation factor 2α (eIF2α) kinase, impairs the ventricular adaptatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yue, Lei, Tong, Yuan, Juntao, Wu, Yongguang, Shen, Xiyue, Gao, Junling, Feng, Wei, Lu, Zhongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006681/
https://www.ncbi.nlm.nih.gov/pubmed/29660505
http://dx.doi.org/10.1016/j.redox.2018.04.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006681/
https://www.ncbi.nlm.nih.gov/pubmed/29660505
http://dx.doi.org/10.1016/j.redox.2018.04.009

Ejemplares similares